Ruplizumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 464384589

| type = mab

| mab_type = mab

| source = zu/o

| target = CD154

| tradename = Antova

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 220651-94-5

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 562JQF15GN

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,{{cite journal | vauthors = Liossis SN, Sfikakis PP | title = Costimulation blockade in the treatment of rheumatic diseases | journal = BioDrugs | volume = 18 | issue = 2 | pages = 95–102 | year = 2004 | pmid = 15046525 | doi = 10.2165/00063030-200418020-00003 | s2cid = 24762590 }} while another study only found thrombocytopenia.{{cite journal | vauthors = Nakamura M, Tanaka Y, Satoh T, Kawai M, Hirakata M, Kaburaki J, Kawakami Y, Ikeda Y, Kuwana M | display-authors = 6 | title = Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism | journal = Rheumatology | volume = 45 | issue = 2 | pages = 150–6 | date = February 2006 | pmid = 16188945 | doi = 10.1093/rheumatology/kei118 | doi-access = free }}